Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of HHT201 in Healthy Subjects
NCT06373094Phase 1Not yet recruiting
- Sponsor
- Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of donepezil in Alzheimer's disease (AD) (6 arms), sponsored by Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Primary endpoints: Adverse events up to 42 days, Number of Participants With Abnormal Laboratory Values up to 42 days and 4 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06373094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373094.